Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine Add-On Therapy in Schizophrenia
NCT00071747Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Lamotrigine with Placebo (2 arms). Primary endpoint: Positive and Negative Symptom Scale Positive Symptom Subscale at 12 weeks. Started Aug 2003; status: completed.
02
Drugs
lamotrigine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00071747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071747.